Patients undergo first doses of GE HealthCare's PET radiotracer Flyrcado (flurpiridaz F 18) injection at early adopter sites ...
GE HealthCare has delivered the initial subject doses of a positron emission tomography (PET) myocardial perfusion imaging ...
GE HealthCare (GEHC) has delivered the first patient doses of Flyrcado or flurpiridaz F 18 njection, a first-of-its-kind unit dose positron ...
Hosted on MSN15d
GE HealthCare projects $4.61-$4.75 adjusted EPS for 2025 amid margin expansion and Flyrcado launchThe company announced the planned launch of Flyrcado, a radiopharmaceutical product for myocardial perfusion imaging, in April 2025. It is expected to generate $30 million in revenue for 2025 and ...
GE HealthCare has delivered the initial subject doses of a positron emission tomography (PET) myocardial perfusion imaging (MPI) agent, Flyrcado (flurpiridaz F 18) injection, to detect coronary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results